164 related articles for article (PubMed ID: 28901547)
1. Cognitive functioning following one-year natalizumab treatment: A non-randomized clinical trial.
Rorsman I; Petersen C; Nilsson PC
Acta Neurol Scand; 2018 Jan; 137(1):117-124. PubMed ID: 28901547
[TBL] [Abstract][Full Text] [Related]
2. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
Sundgren M; Piehl F; Wahlin Å; Brismar T
Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
[TBL] [Abstract][Full Text] [Related]
3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
[TBL] [Abstract][Full Text] [Related]
4. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
6. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
7. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P; Viterbo RG; Paolicelli D; Lucchese G; Portaccio E; Goretti B; Direnzo V; D'Onghia M; Zoccolella S; Amato MP; Trojano M
PLoS One; 2012; 7(4):e35843. PubMed ID: 22558238
[TBL] [Abstract][Full Text] [Related]
8. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
9. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
[TBL] [Abstract][Full Text] [Related]
10. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
Wickström A; Dahle C; Vrethem M; Svenningsson A
Mult Scler; 2014 Jul; 20(8):1095-101. PubMed ID: 24378984
[TBL] [Abstract][Full Text] [Related]
11. Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings.
Mattioli F; Stampatori C; Bellomi F; Scarpazza C; Capra R
PLoS One; 2015; 10(7):e0131803. PubMed ID: 26148120
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
13. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.
Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK
Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
[TBL] [Abstract][Full Text] [Related]
15. Clinical and radiological control of highly active relapsing-remitting multiple sclerosis with first-line natalizumab.
Meca-Lallana JE; Carreón-Guarnizo E; Hernández-Clares R; García-Molina E; Díaz-Pérez J; Leon-Hernández A; Zamarro-Parra J; Martín-Fernández JJ
Neurodegener Dis Manag; 2017 Jun; 7(3):175-181. PubMed ID: 28592169
[TBL] [Abstract][Full Text] [Related]
16. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.
Mattioli F; Stampatori C; Capra R
Neurol Sci; 2011 Feb; 32(1):83-8. PubMed ID: 20872033
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
[TBL] [Abstract][Full Text] [Related]
18. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
19. Translational validity of PASAT and the effect of fatigue and mood in patients with relapsing remitting MS: A functional MRI study.
Iancheva D; Trenova AG; Terziyski K; Kandilarova S; Mantarova S
J Eval Clin Pract; 2018 Aug; 24(4):832-838. PubMed ID: 29611255
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab.
Fagius J; Feresiadou A; Larsson EM; Burman J
Mult Scler Relat Disord; 2017 Feb; 12():82-87. PubMed ID: 28283113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
